# Cardiorenal Disease: Protect the Heart and Kidney Together

Preserve indicated therapy by distinguishing manageable changes from genuine contraindications, and link each initiation to a specific monitoring plan.

![Infographic: Cardiorenal Disease: Protect the Heart and Kidney Together](https://urinenephrology.org/visual-reference/images/student-cardiorenal-gdmt.png?v=20261003c)

## Define two phenotypes

Record EF and clinical heart-failure evidence alongside eGFR, UACR, potassium, BP, congestion, and perfusion. HFrEF, HFpEF, and albuminuric CKD overlap but do not carry identical drug indications. Diuretics treat fluid retention; they do not replace disease-modifying therapy.

## HFrEF: build four complementary classes

When eligible and tolerated, use ARNI/ACE inhibitor/ARB, an evidence-based beta blocker, a steroidal MRA, and an SGLT2 inhibitor. Start and titrate around BP, pulse, volume, potassium, kidney function, and follow-up capacity; one universal sequence is unnecessary.

## MRA selection has boundaries

For symptomatic HFrEF, spironolactone/eplerenone initiation requires eGFR >30 and K <5.0 mEq/L, with close follow-up. Stop if potassium cannot be maintained below 5.5. Finerenone has distinct diabetes/CKD and HF evidence; it is not automatically an interchangeable HFrEF substitute.

## A creatinine rise needs a diagnosis

During effective decongestion, a modest rise with improving edema and maintained perfusion differs from shock, oliguria, or progressive injury. After ACE/ARB initiation, a rise >30% within 4 weeks triggers assessment for depletion, NSAIDs, AKI, or renovascular disease.

## Revisit an old discontinuation

Reconsider protective therapy stopped after asymptomatic positive urine findings. Verify whether there was actual infection, symptomatic hypotension, severe hyperkalemia, or another contraindication. Restart eligible treatment with a dated BP, creatinine, potassium, and symptom review.

## Measure the benefit relevant to this patient

SGLT2 therapy can be indicated despite HbA1c at target. Check drug-specific kidney eligibility and hold guidance during fasting, surgery, or critical illness. Do not attribute an individual eGFR decline entirely to a past drug stop or promise additive percentages across trials.

## Supporting evidence

- [Supporting guideline or source](https://professional.heart.org/en/guidelines-statements/2022-ahaacchfsa-guideline-for-the-management-of-heart-failure-a-report-of-thecir0000000000001063)
- [Supporting guideline or source](https://kdigo.org/wp-content/uploads/2026/04/KDIGO-2024-CKD-Guideline.pdf)

## Source lessons

- [chapter 18 cardiorenal](https://urinenephrology.org/nephrology-textbook/chapters/chapter-18-cardiorenal.html)
- [cardiorenal syndrome student handout](https://urinenephrology.org/student-resources/cardio-renal/cardiorenal-syndrome-student-handout.html)
- [gdmt student handout](https://urinenephrology.org/student-resources/cardio-renal/gdmt-student-handout.html)

Read alongside the full lessons; the findings and decisions shown here require the stated clinical context.